TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 01, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will present a corporate overview and host investor meetings during the Jefferies Healthcare Conference, held in New York City, from June 6 - 9, 2017.
Matt Kapusta, chief executive officer, will present on Friday, June 9, 2017 at 8:00 am EDT. The live webcast of the presentation can be accessed through the link displayed in the Investor Section of uniQure website at http://uniqure.com/investors-newsroom/events-presentations.php. A replay of the webcast will be available within 24 hours following the event, and will remain available for at least two weeks.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected]
